Matt Hoffman

New data suggest a switch from natalizumab to a high efficacy disease-modifying therapy for patients with multiple sclerosis is more beneficial than switching to moderate efficacy therapy, including a lower risk of disease activity.

Despite the conventional need for patients to travel to MRI devices, the use of a point-of-care, portable scanner has proven to be a feasible method of acquiring clinically useful images.

In addition to significant improvements compared to placebo on Quantitative QMG scores, zilucoplan improved patients' activities of daily living and quality of life scores.

These data confirm the need for consideration of these costs when prescribing treatments, and is of considerable importance as out of pocket costs continue to rise in the US.

The Prometra II offers a pressure-driven, valve-gated delivery mechanism that allows for novel programming modes of intermittent flow followed by periods of no flow—a feature unique to this device.

The chronic migraine preventive, despite falling short of efficacy end points, was safe and well-tolerated in a small cohort of patients aged 12 to 17 years.

The vice president of Medical Affairs at Adamas Pharmaceuticals discussed the context of these results and what the clinical community should take away from the data from the EASE LID 2 trial of amantadine (Gocovri).

This novel trial’s positive outcome suggests that a multidisciplinary outpatient model is possible to integrate into care beyond just those who are most vulnerable in institutional care.

Neurofilament light chain has emerged as a biomarker with utility across the breadth of neurology, but just how much can it actually help?

Following the 2011 guideline development process, this 2020 guideline focused on addressing a number of types of sleep disturbance in children and adolescents with autism spectrum disorder.

Final results of the EASE LID 2 study suggest that amantadine (Gocovri; Adamas) extended-release capsules are safe and effective over a 2-year treatment period.

New findings suggest a strong association between certain lower extremity biomarkers and measures of clinical function in patients with Duchenne muscular dystrophy.

The Aquestive Therapeutics diazepam formulation is seeking to be second to market in the treatment of seizure clusters, with a targeted prescription drug user fee action date of September 27, 2020.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Daniel Hartung, PharmD, MPH.

Compared with healthy individuals, those with cluster headache are significantly more likely to experience sickness absence and disability pension days, with women more impacted than men.

The lead author of a recent publication from the Memory and Aging Project discussed the data and what impact flavonol intake might have on the risk of developing Alzheimer disease dementia.

The investigational therapy met its primary end point, showing superiority to placebo in reducing the frequency of drop seizures in patients with Lennox-Gastaut syndrome.

This additional application, supported by data from the GWPCARE6 trial, seeks to expand the indication of cannabidiol to include seizures associated with tuberous sclerosis complex.

New retrospective data suggest that patients with MS who have comorbid conditions have increased all-cause hospital admission rates, especially early in the disease.

The software, developed by Qynapse, provides analysis of brain MRI markers in diseases such as Alzheimer disease, Parkinson disease, and multiple sclerosis.

New Medicare data has suggested that those with undiagnosed obstructive sleep apnea have higher annual health care costs than their counterparts, with this high economic burden accompanying already impacted function and quality of life.

The software, developed by Qynapse, provides analysis of brain MRI markers in diseases such as Alzheimer disease, Parkinson disease, and multiple sclerosis.

This additional application, supported by data from the GWPCARE6 trial, seeks to expand the indication of cannabidiol to include seizures associated with tuberous sclerosis complex.

The lead author of a recent publication from the Memory and Aging Project discussed the data and what impact flavonol intake might have on the risk of developing Alzheimer disease dementia.

New data has suggested that although adherence rates for CPAP for patients with OSA are lower than ideal, the benefits patients receive from its use can still be significant.

The director of headache services at NYU Langone discussed the 2019 American College of Emergency Physicians guidelines on acute nontraumatic headache in the emergency department.

Data from the Memory and Aging Project suggests that dietary intake of flavonols, a type of phytochemical often found in plant pigment, is significantly linked to a lower risk of Alzheimer disease dementia.

Using the Sleepio intervention resulted in significantly greater improvement in insomnia symptoms, as well as almost all other outcomes assessed, in women who were pregnant with insomnia.

Data from the MS SMART trial, which may serve as a template for simultaneous testing of multiple DMTs, suggest that exclusively targeting axonal pathobiology is inadequate to prevent neuroaxonal loss.

New study data showed nerve ultrasound had a sensitivity of 97.4% and specificity of 78.9%, with an added value in the detection of treatment-responsive chronic inflammatory neuropathy of 21.1%.